Amgen Inc

Industry:	Pharmaceuticals, Biotechnology
Ranking:	Russell 3000, Fortune 500
Revenues:	$14.8 Billion
Employees:	17,500

Description

Amgen Inc. is a biotechnology company that discovers, develops, manufactures and markets human therapeutics-based on advances in cellular and molecular biology. The Company operates in human therapeutics. It markets human therapeutic products in the areas of supportive cancer care, nephrology, inflammation and oncology. Its principal products include Aranesp (darbepoetin alfa), EPOGEN (Epoetin alfa), Neulasta (pegfilgrastim), NEUPOGEN (Filgrastim) and Enbrel (etanercept). Aranesp and EPOGEN stimulate the production of red blood cells to treat anemia and belong to a class of drugs referred to as erythropoiesis-stimulating agents (ESAs). Other marketed products principally consists of Sensipar (cinacalcet HCl) and Vectibix (panitumumab). On July 16, 2007, the Company acquired Alantos Pharmaceuticals Holding, Inc.
(Source: 10-K)

Find More Jobs

Job Openings

Associate Scientist, Thousand Oaks, CA - NB50965048 Thousand Oaks , CA

Biostatistical Programming Sr Mgr (Submission Data Standards) Thousand Oaks San Francisco Seattle NB50958309 Thousand Oaks , CA

Medical Communications Director - NB50839665 Thousand Oaks , CA

Sr Biopharmaceutical Sales Rep, Oncology - Asheville, NC - NB51008995 Asheville , NC

Associate Regulatory Affairs - NB50960507 Thousand Oaks , CA

View More Statistics

Site Statistics

Monthly Unique Visitors:	48,437
Site Rank:	40,432
Trust Rating:	Trusted
Stats by

News Archive

Amgen Scholars Europe Programme Convenes Undergraduates From 15 Countries for Innovative Science Research. PR Newswire Europe; 9/16/2009 ...the University of Cambridge for the first Amgen Scholars European Symposium with the common...generation of leading scientists. The first Amgen Scholars Europe class represents 35 different...Switzerland, Turkey, and the UK. "Amgen Scholars is a one-of-a-kind programme... ...more

Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO). PR Newswire; 7/27/2009 Amgen to Retain Full Rights for Denosumab in the...July 27 /PRNewswire-FirstCall/ -- Amgen and GlaxoSmithKline (GSK) today announced...companies will share commercialization of Amgen's monoclonal antibody denosumab for postmenopausal... ...more

Amgen Scholars Discover Their Potential During Summer Science Research Program and National Symposium. PR Newswire; 7/20/2009 ...students met at UCLA for the third annual Amgen Scholars U.S. Symposium designed to...day symposium is a key component of the Amgen Scholars Program, a $27.5 million initiative...During the symposium, hosted by the Amgen Foundation in collaboration with the Massachusetts... ...more